AKBA: Akebia Company Value to Net Income

Corporate emblem and logo of Akebia (AKBA)

The investment potential of Akebia Therapeutics (AKBA) is bolstered by the implementation of energy-saving technologies and emission filtration in its laboratories. The business's current P/E ratio illustrates the stock price dynamics relative to earnings, where -2.50 captures the current value of the indicator. Efficiency is confirmed by the scaling of Vafseo sales through Medicare, while the cyclical recovery phase and regulatory successes ensure stable revenue growth.

Akebia Therapeutics, Inc. (AKBA): P/E Multiple from 07/04/2022 to 11/18/2026

Analytical breakdowns for Akebia Therapeutics

- price and consensus price forecast:
- market capitalization information:
Summary company analysis:AKBA (Akebia)
Product sample of akebia.com

High scalability of kidney disease treatments with minimal costs allows Akebia Therapeutics (AKBA) to generate significant cash flow. The ratio of market capitalization to net income, represented by the price-to-earnings ratio, measures the cost of one dollar of earnings, helping investors identify asset overvaluation or hidden delisting risks in the event of a sharp decline in the multiple.